# Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

> **NCT02296190** · PHASE2 · COMPLETED · sponsor: **Milestone Pharmaceuticals Inc.** · enrollment: 199 (actual)

## Conditions studied

- Paroxysmal Supraventricular Tachycardia (PSVT)

## Interventions

- **DRUG:** Etripamil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02296190
- **Lead sponsor:** Milestone Pharmaceuticals Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-27
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2020-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296190, "Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02296190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*